Long Covid Labs
COVIDUpcoming DAO

Accelerating a cure for 100M Long COVID patients. By incentivizing scientists, patients and supporters to collaborate and share data, we’re creating an open marketplace for rapid R&D and commercialization of new treatments for Long COVID. Our first treatment launches January 2025.

Learn more:

Banner background
Genesis auction is live!

Participate in the $COVID genesis auction and become part of Long Covid Labs

Go to Auction
Market Hypothesis

400 Million

Global cumulative patient population

$1 Trillion

Global Cost Yearly

Zero

Number of Long COVID treaments approved

Long COVID is the fastest-growing chronic health condition in human history. It's already estimated to cost the global economy more than $1 trillion dollars or 1% of global GDP each year.



10% of COVID infections result in Long COVID. The virus can be found in the body and brain for years after the initial infection, potentially causing worrying health effects in Long COVID and beyond....

Research Focus Areas
Repurposing Existing Antivirals and Antibodies

Repurposing Existing Antivirals and Antibodies

Focusing on quickly testing and repurposing existing FDA-approved drugs, as well as Broadly Neutralizing Antibodies (bNAbs) to target persistent viral reservoirs in Long COVID patients.


Developing Long-Acting Antibody (LAAb) Therapies

Developing Long-Acting Antibody (LAAb) Therapies

Exploring research and trials for Long-Acting Antibody treatments that could prevent reinfection and manage viral persistence. These therapies could be integrated with COVID vaccines for dual protection.


Open Therapeutics Platform for Breakthrough Discoveries

Open Therapeutics Platform for Breakthrough Discoveries

Building an open platform for decentralized scientific collaboration to identify and test experimental, high-risk, high-reward therapies. This includes funding innovative ideas from researchers worldwide, enabled by DAO governance and resource sharing.


Team & Community
Rohan Dixit

Rohan Dixit

Neuroscience at Stanford and the Harvard-MIT-MGH Martinos Center.

Long COVID patient and self-experimenter. Serial healthcare and med device entrepreneur. Formerly neuroscientist at Stanford and the Harvard-MIT-MGH M...

Ruth Ann Crystal

Ruth Ann Crystal

MD

Stanford physician entrepreneur, runs one of the largest COVID-19 newsletters. Stanford StartX mentor with interests in healthcare innovation and huma...

Jacob Glanville

Jacob Glanville

Ph.D., Founder at Centivax, Distributed Bio

Computational immunoengineer, founder at Centivax, Distributed Bio. Recipient of Gates Foundation Grand Challenge "Ending the Pandemic Threat"...

Annelise Barron

Annelise Barron

Ph.D.

W.M. Keck Professor of Bioengineering at Stanford. Immune dysregulation and novel COVID-19 therapeutics. Pioneer in peptoid engineering....

@LongCOVIDlabs on 𝕏

Telegram community

Reddit community

Project Roadmap
Q3 2022
Rohan cures himself with combination treatment of monoclonal antibodies and viral replication inhibitor
Q1 2025
Launch via BIO Protocol Launchpad
Q1 2025
5 case studies: Paxlovid + Pemgarda
Q2 2025
30 patient clinical trial
Q3 2025
Scale U.S. commercial roll-out of combination treatments via telemedicine partners
Q4 2025
Moonshot Engine Launch: Adaptive Multi-Intervention trials
Q1 2026
Expand treatment internationally
Q3 2026
Novel LCL bnAb molecules to market
Value Capture Model

Long COVID Labs (LCL) employs a multifaceted value capture model that combines near-term revenue generation with long-term innovation in therapeutics. By repurposing FDA-approved drugs like Paxlovid and leveraging existing antibody technologies, LCL ...

Value Capture Model Diagram
Recommended Reads
Long COVID research risks losing momentum – we need a moonshot

Nature

Long COVID research risks losing momentum – we need a moonshot


Spike Protein Lingers in Brain, Fuels Long COVID

Neuro Science News

Spike Protein Lingers in Brain, Fuels Long COVID


Long COVID science, research and policy

New York Times

Long COVID science, research and policy